Capricor Therapeutics (NASDAQ:CAPR) Upgraded to “Hold” at ValuEngine

ValuEngine upgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a sell rating to a hold rating in a report issued on Thursday morning, ValuEngine reports.

Several other equities research analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Capricor Therapeutics from a buy rating to a hold rating in a research note on Tuesday, July 16th. HC Wainwright lifted their price objective on shares of Capricor Therapeutics from $3.50 to $12.40 and gave the stock a buy rating in a research note on Monday, July 15th. Three research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $5.63.

NASDAQ CAPR traded down $0.16 on Thursday, hitting $3.82. The stock had a trading volume of 43,129 shares, compared to its average volume of 2,304,257. Capricor Therapeutics has a 52-week low of $2.53 and a 52-week high of $12.30. The business has a fifty day moving average of $4.11. The company has a market capitalization of $13.26 million, a PE ratio of -0.73 and a beta of 1.69.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Monday, May 13th. The biotechnology company reported ($0.08) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.03. Capricor Therapeutics had a negative net margin of 936.22% and a negative return on equity of 225.30%. The business had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.40 million. Sell-side analysts predict that Capricor Therapeutics will post -3 EPS for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Read More: Arbitrage

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with's FREE daily email newsletter.